Stay updated with breaking news from Acquiring all. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Depression Scores Did Not Differ Significantly Between Patients Who Used Psilocybin or Escitalopram at 6 weeks These findings, from a phase 2, double-blind, randomized, controlled trial, were published in the New England Journal of Medicine. Patients (N=59) with long-standing, moderate to severe major depressive disorder were recruited via an advertisement in the United Kingdom in 2019. Patients were randomized to receive 2 doses of 25 mg psilocybin with a daily placebo for 6 weeks (n=30) or 2 doses of 1 mg psilocybin with 3 weeks of daily 10 mg escitalopram and 3 weeks of 20 mg escitalopram (n=29). Patients were assessed by magnetic resonance imaging (MRI) and performed cognitive and affective processing tasks. ....
Creso Announced That its Total Q1 2021 Revenue Was A$1,385,000 – up 237% From Q4 2020 Creso Pharma (ASX: CPH) (OTC:COPHF) (FRA: 1X8) announced the release of its Quarterly Activities Report for the period ended 31 March 2021, together with its Appendix 4C Quarterly Cash Flow Report. “This quarter marked Creso’s evolution into a broader-based pharmaceutical company. Having undertaken a thorough search for quality, complementary acquisition opportunities, the company successfully identified and secured an agreement with psychedelics company, Halucenex, which, if approved by shareholders, will represent a significant milestone for the company, as it looks to commercialize new psychedelic-assisted psychotherapy treatments. Halucenex has made considerable progress during the quarter and provides Creso with access to another lucrative vertical,” said Adam Blumenthal, Creso Pharma Non-Executive Chairman. ....